GlassScriptPhysician profile
Catherine Crosby
NPI 1316308794
$2,447.66
in general payments reported to CMS, 2019-2025
26 companies · $993 in 2025
The $993 reported for 2025 was more than what 80% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $173 · 2022: $614 · 2023: $75.23 · 2024: $593 · 2025: $993.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,661.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,660.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $419.23 | 2021-2025 | Mounjaro, Kisunla, Reyvow |
| Abbvie INC. | $329.21 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $235.95 | 2024-2025 | Xarelto, Spravato |
| Eisai INC. | $145.09 | 2022-2025 | |
| Glaxosmithkline, LLC. | $142.35 | 2022 | |
| Novo Nordisk INC | $133.89 | 2022-2025 | Ozempic |
| E.R. Squibb & Sons, L.L.C. | $125.99 | 2025 | Cobenfy |
| Biohaven Pharmaceutical Holding Company LTD. | $125.00 | 2022 | |
| Averitas Pharma INC. | $119.68 | 2024 | Qutenza |
| Tg Therapeutics, INC. | $107.75 | 2024 | |
| Acadia Pharmaceuticals INC | $105.55 | 2025 | Nuplazid |
| Ucb, INC. | $96.75 | 2024 | Rystiggo |
| Lundbeck LLC | $69.44 | 2025 | Vyepti |
| Inari Medical, INC. | $44.59 | 2023 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Takeda Pharmaceuticals U.S.A., INC. | $37.73 | 2022 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $32.94 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $29.13 | 2021 | |
| Hologic Sales and Service, LLC | $24.49 | 2021 | |
| Therapeuticsmd, INC. | $20.74 | 2022 | |
| Ultragenyx Pharmaceutical INC. | $18.18 | 2022 | |
| Organon LLC | $17.83 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $14.66 | 2021 | |
| Avion Pharmaceuticals | $13.22 | 2021 | |
| Currax Pharmaceuticals LLC | $13.18 | 2021 | |
| Seqirus USA INC | $12.66 | 2021 | |
| Evofem Biosciences, INC. | $12.43 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Catherine Crosby listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.